ATE219942T1 - Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält - Google Patents

Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält

Info

Publication number: ATE219942T1
Authority: AT; Austria
Prior art keywords: powder formulation; drying; containing crystalline; use containing; crystalline insulin
Prior art date: 1997-03-20

Application number

AT98907915T

Other languages

English (en)

Inventor

Steen Jensen

Philip Hansen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-20

Filing date

1998-03-20

Publication date

2002-07-15

1998-03-20 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2002-07-15 Application granted granted Critical

2002-07-15 Publication of ATE219942T1 publication Critical patent/ATE219942T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
239000000843 powder Substances 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 3
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
230000002685 pulmonary effect Effects 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title abstract 2
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
238000001035 drying Methods 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
238000004108 freeze drying Methods 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
210000002345 respiratory system Anatomy 0.000 abstract 1
238000001694 spray drying Methods 0.000 abstract 1
238000001291 vacuum drying Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT98907915T 1997-03-20 1998-03-20 Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält ATE219942T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK31997		1997-03-20
PCT/DK1998/000108 WO1998042368A1 (en)	1997-03-20	1998-03-20	Therapeutic powder formulation for pulmonary administration, containing crystalline insulin

Publications (1)

Publication Number	Publication Date
ATE219942T1 true ATE219942T1 (de)	2002-07-15

Family

ID=8092222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98907915T ATE219942T1 (de)	1997-03-20	1998-03-20	Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält

Country Status (6)

Country	Link
EP (1)	EP0971729B1 (de)
JP (1)	JP2001518916A (de)
AT (1)	ATE219942T1 (de)
AU (1)	AU6611998A (de)
DE (1)	DE69806362T2 (de)
WO (1)	WO1998042368A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999055310A1 (en)	1998-04-27	1999-11-04	Altus Biologics Inc.	Stabilized protein crystals, formulations containing them and methods of making them
US6635617B1 (en)	1998-10-16	2003-10-21	Novo Nordisk A/S	Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
DK1121145T3 (da) *	1998-10-16	2002-08-12	Novo Nordisk As	Insulinpræparater til indgivelse via lungerne, som indeholder mentol
UA65636C2 (uk) *	1998-10-16	2004-04-15	Ново Нордіск А/С	Стабільні концентровані препарати інсуліну для доставки через легені
US6350432B1 (en) *	1999-03-19	2002-02-26	Generex Pharmaceuticals Incorporated	Pressurized container having an aerosolized pharmaceutical composition
JP2002543092A (ja) *	1999-04-27	2002-12-17	イーライ・リリー・アンド・カンパニー	肺投与用インスリン結晶
AU5454200A (en) *	1999-06-29	2001-01-31	Eli Lilly And Company	Protamine-free insoluble acylated insulin compositions
EP1196445A1 (de) *	1999-06-29	2002-04-17	Eli Lilly And Company	Insulinkristalle zur verabreichung über die lunge
US20040265238A1 (en) *	2003-06-27	2004-12-30	Imtiaz Chaudry	Inhalable formulations for treating pulmonary hypertension and methods of using same
CA2531988C (en)	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
JP2006199589A (ja) *	2003-09-03	2006-08-03	Ltt Bio-Pharma Co Ltd	生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
US7658721B2 (en)	2004-01-16	2010-02-09	Biodel Inc.	Sublingual drug delivery device
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
ES2371361T3 (es)	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
JP5552046B2 (ja) *	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
JP4959005B2 (ja)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2991672A1 (de)	2013-04-30	2016-03-09	Novo Nordisk A/S	Neuartiges verabreichungsschema
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2933946A1 (de) *	1979-08-22	1981-03-12	Hoechst Ag, 6000 Frankfurt	Insulinkristallsuspension und verfahren zu ihrer herstellung.
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5597893A (en) *	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations

1998
- 1998-03-20 JP JP54474698A patent/JP2001518916A/ja active Pending
- 1998-03-20 AT AT98907915T patent/ATE219942T1/de not_active IP Right Cessation
- 1998-03-20 WO PCT/DK1998/000108 patent/WO1998042368A1/en not_active Ceased
- 1998-03-20 EP EP98907915A patent/EP0971729B1/de not_active Expired - Lifetime
- 1998-03-20 DE DE69806362T patent/DE69806362T2/de not_active Expired - Fee Related
- 1998-03-20 AU AU66119/98A patent/AU6611998A/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2001518916A (ja)	2001-10-16
DE69806362D1 (de)	2002-08-08
WO1998042368A1 (en)	1998-10-01
EP0971729B1 (de)	2002-07-03
EP0971729A1 (de)	2000-01-19
AU6611998A (en)	1998-10-20
DE69806362T2 (de)	2003-01-30

Legal Events

Date	Code	Title	Description
2003-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE219942T1 (de)	2002-07-15	Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
GB2240337B (en)	1993-02-24	Aerosol carriers
AU6611898A (en)	1998-10-20	Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
YU59092A (sh)	1994-12-28	Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
CA2346791A1 (en)	2000-04-20	Flow resistance modulated aerosolized active agent delivery
KR970703366A (ko)	1997-07-03	인터페론의 건조 분말 제형물을 제조하기 위한 방법 및 조성물(methods and compositions for the dry powder formulation of interferons)
YU59192A (sh)	1994-12-28	Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
IS1768B (is)	2001-05-02	Lyfjablanda til innöndunar sem inniheldur insúlín
IS4179A (is)	1994-12-25	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW329387B (en)	1998-04-11	Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
TR200002692T2 (tr)	2001-02-21	Aerosol haline getirilen aktif maddenin verilmesi.
PL316199A1 (en)	1996-12-23	Methods of and compositions for administering insulin into lungs
LT2001021A (en)	2001-11-26	Dry powder active agent pulmonary delivery
GB0008660D0 (en)	2000-05-31	The treatment of respiratory diseases
CA2226657A1 (en)	1997-02-06	Improvements in and relating to powders for use in dry powder inhalers
DE69205177D1 (de)	1995-11-02	Pharmazeutische Aerosolformulierung.
DE69738000D1 (de)	2007-09-20	Neue Arzneiformulierung enthaltend Budesonide
BR9709845B1 (pt)	2008-11-18	preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
ATE137958T1 (de)	1996-06-15	Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen
DE69200711D1 (de)	1995-01-05	Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69705414D1 (de)	2001-08-02	Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
ATE417599T1 (de)	2009-01-15	Pharmazeutische zubereitung zur intranasalen applikation von proteinen, enthaltend chitosan oder eines seiner derivate
ATE196914T1 (de)	2000-10-15	Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
WO2005041852A3 (en)	2006-05-18	Keratin gel and the types 2, 4 and 6 of collagens of frog protein
ATE284696T1 (de)	2005-01-15	Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten